Search Within

Gunjan Lalitchandra Shah

Formats
  1. Meeting Abstract (290)
  2. Journal Article (129)
  3. Research Letter (15)
  4. Review (6)
  5. Correspondence (2)
  6. Guidelines (1)
Groups
  1. Bone Marrow Transplant (443)
  2. Center for Hematologic Malignancies (443)
  3. Department of Medicine (443)
  4. Hematologic Malignancies, Division of (443)
  5. Survivorship Research (443)
  6. CTCR Scholars (341)

More Groups

People
  1. Sergio Giralt (308)
  2. Michael Scordo (296)
  3. Miguel-Angel Perales (204)
  4. Sean Devlin (187)
  5. Parastoo Dahi (163)
  6. Heather Landau (161)

More People

Years
  1. 2025 (19)
  2. 2024 (72)
  3. 2023 (85)
  4. 2022 (55)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Blood (156)
  2. Biology of Blood and Marrow Transplantation (73)
  3. Clinical Lymphoma, Myeloma and Leukemia (39)
  4. Transplantation and Cellular Therapy (23)
  5. Blood Advances (21)
  6. Bone Marrow Transplantation (19)

More Publications

Publishers
  1. American Society of Hematology (177)
  2. Elsevier Inc. (142)
  3. Nature Publishing Group (32)
  4. American Society of Clinical Oncology (15)
  5. Taylor & Francis Group (9)
  6. Wiley Blackwell (7)

More Publishers

Results (443)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Antithymocyte globulin exposure in CD34(+) T-cell–depleted allogeneic hematopoietic cell transplantation
    Journal Article

    Lakkaraja, M.; Scordo, M.; Mauguen, A.; Cho, C.; Devlin, S.; Ruiz, J. D.; Klein, E.; Avecilla, S. T.; Boulad, F.; Cancio, M. I.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save
  • Novel agents may be preferable to chemotherapy for large B-cell lymphoma progressing after CD19-CAR-T: A multicenter observational study
    Meeting Abstract

    Tomas, A. A.; Fein, J. A.; Fried, S.; Fingrut, W.; Anagnostou, T.; Alperovich, A.; Shah, N.; Fraint, E.; Lin, R. J.; Scordo, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Timing and immune status after cellular therapies predict response to COVID-19 vaccines
    Meeting Abstract

    Tamari, R.; Politikos, I.; Knorr, D.; Vardhana, S.; Young, J.; Marcello, L.; Doddi, S.; Devlin, S. M.; Ramanathan, L.; Pessin, M. S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Five-year experience using bridging radiotherapy prior to chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Silverman, E. A.; Hubbeling, H.; Palomba, M. L.; Wijetunga, N. A.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide maintenance therapy for multiple myeloma: A randomized pilot study comparing patient-reported health related quality of life measures
    Meeting Abstract

    Shah, U. A.; Malik, M.; Werner, K.; Burge, M.; Devlin, S. M.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)
    Meeting Abstract

    Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy
    Meeting Abstract

    Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world experience
    Meeting Abstract

    Hultcrantz, M.; Orozco, J.; Peterson, T. J.; Derkach, A.; Hassoun, H.; Korde, N.; Lu, S. X.; Mailankody, S.; Patel, D.; Shah, U. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Successful incorporation of electronic patient-reported outcomes using PROMIS-29 into standard of care for lymphoma patients receiving CD19-directed chimeric antigen receptor T (CAR T) cell therapy
    Meeting Abstract

    Shah, G. L.; Scordo, M.; Sauter, C.; Batlevi, C.; Dahi, P. B.; Lin, R.; Palomba, M. L.; Perales, M. A.; Giralt, S. A.
    Quality of Life Research (2021)

    Fulltext@MSK | Save